NAC (N-Acetyl Cysteine) for Fatty Liver (NAFLD)
Acetylated form of the amino acid cysteine and the rate-limiting precursor for glutathione, the body's principal antioxidant; used clinically as the antidote for paracetamol overdose and studied for respiratory and mental health.
The connection
Non-alcoholic fatty liver disease. Fat accumulation in the liver, often linked to insulin resistance and obesity.
Also known as: NAC, N-Acetyl-L-Cysteine
NAC (N-Acetyl Cysteine) × Fatty Liver (NAFLD): at a glance
Every published result for this pair, extracted and audited.
NAC (N-Acetyl Cysteine) / Fatty Liver (NAFLD): publication years
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Publications (count) |
|---|---|
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
NAC (N-Acetyl Cysteine) × Fatty Liver (NAFLD): the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysisPetrelli F, et al. · Urologic oncology · 2026PMID 40935764 ↗02The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trialsEghdami S, et al. · Frontiers in psychiatry · 2024PMID 39376972 ↗03The impact of N-acetylcysteine on lactate, biomarkers of oxidative stress, immune response, and muscle damage: A systematic review and meta-analysisSadowski M, et al. · Journal of cellular and molecular medicine · 2024PMID 39632267 ↗04Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatmentde Oliveira MVS, et al. · Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2023PMID 36749887 ↗05Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysisLlano-León M, et al. · PloS one · 2023PMID 37104271 ↗06Clinical Recommendations for Augmentation Agents in Obsessive-Compulsive Disorder Partially Responsive to Serotonin Reuptake InhibitorsGautam M · Journal of clinical psychopharmacology · 2023PMID 37335203 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.